FIELD: medicine.
SUBSTANCE: group of inventions relates to aqueous tumour-targeted compositions of nanoparticles containing legumain-targeted lipid, containing a lipid component covalently bonded with binding legumain group, where binding legumain group includes legumain inhibitor type aza-Asn peptide with reactive part of presented formula (I):
,
as well as use thereof to treat expressing legumain tumour diseases.
EFFECT: group of inventions eliminated risks associated with targeting using ligands, while providing effective agents for tumour-specific drug delivery.
16 cl, 11 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FERRITIN NANOPARTICLES CONTAINING CHEMOTHERAPEUTIC AGENT | 2019 |
|
RU2810594C2 |
| LIPOSOMAL COMPOSITIONS APPLICABLE FOR DRUG DELIVERY | 2005 |
|
RU2574926C2 |
| LIPOSOMAL COMPOSITIONS USED FOR DRUG DELIVERY | 2015 |
|
RU2757110C2 |
| DNA COMPOSITION FOR INDUCING IMMUNE RESPONSE ON TUMOUR-ASSOCIATED MACROPHAGUES | 2007 |
|
RU2459631C2 |
| MODULAR PARTICLES FOR IMMUNOTHERAPY | 2014 |
|
RU2672055C2 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| MAGNETIC METAL OXIDE COATED POLYMER NANOPARTICLES AND USE THEREOF | 2008 |
|
RU2472530C2 |
| ANTHRACYCLINE-ANTIBODY CONJUGATES | 2004 |
|
RU2349343C2 |
| DOXORUBICIN-GOLD NANOCONJUGATES WITH DIRECTIONAL INFLUENCE FOR TUMOR THERAPY | 2018 |
|
RU2773707C2 |
| BACTERIALLY DERIVED, INTACT MINICELLS FOR DELIVERY OF THERAPEUTIC AGENTS TO BRAIN TUMOURS | 2012 |
|
RU2664698C2 |
